Alectinib is a targeted medicine in capsule form for non-small cell lung cancer whose cells carry a rearranged ALK gene ('ALK-positive'). It is used as a first treatment for advanced ALK-positive lung cancer, after crizotinib has stopped working, and — more recently — after surgery for early-stage ALK-positive disease to reduce the chance of the cancer returning.
ALK-positive lung cancer often spreads to the brain, and alectinib was designed to cross into the brain, where many earlier drugs could not reach. Your tumour must have been tested for the ALK rearrangement before it is prescribed.
Alectinib is taken twice a day with food, continuously. Muscle aches, constipation, swelling and raised liver enzymes are the side effects your oncologist watches for. It is a prescription-only medicine; a valid prescription must be provided at checkout.